The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-β signaling

Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future

Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy

Oncolytic virus therapy for cancer: the first wave of translational clinical trials

Two avirulent, lentogenic strains of Newcastle disease virus are cytotoxic for some human pancreatic tumor lines in vitro

The use of oncolytic viruses to overcome lung cancer drug resistance

Newcastle disease virus: a promising agent for tumour immunotherapy

Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization

Cell-type-specific innate immune response to oncolytic Newcastle disease virus

Recent clinical experience with oncolytic viruses